No Established Normal Reference Values for Total Lesion Glycolysis
There are no established normal reference values for total lesion glycolysis (TLG) because TLG is a tumor-specific metabolic parameter that measures the product of metabolic tumor volume and mean standardized uptake value—it is only calculated when FDG-avid lesions (tumors) are present. 1
Understanding TLG as a Tumor-Specific Metric
TLG is fundamentally different from other laboratory values that have normal ranges. According to EANM guidelines, TLG is calculated as the product of metabolic tumor volume (MTV) multiplied by the mean SUV (SUVmean) within a defined volume of interest around FDG-avid lesions 1. This calculation requires:
- A 3D delineation or segmentation of FDG-avid lesions
- Commonly using isocontour thresholds at 41% (TLG41) or 50% (TLG50) of maximum pixel value
- The presence of pathologic FDG uptake to measure
In healthy tissue without tumors, there would be no lesions to measure, making the concept of "normal TLG" meaningless.
Clinical Application: TLG as a Prognostic Tool
Rather than comparing to normal values, TLG is used in several ways:
Prognostic Stratification
Research demonstrates TLG's value in risk stratification across multiple cancers:
- Soft-tissue sarcoma: TLG >250 was independently predictive of disease progression (P = 0.008) 2
- Oral cavity squamous cell carcinoma: Median TLG of 71.4 used to divide patients into high/low risk groups, with 2-year disease-specific survival of 53% vs 84% (P <0.001) 3
- Diffuse large B-cell lymphoma: TLG ≥1,852 independently associated with inferior progression-free and overall survival 4
Longitudinal Monitoring
The EANM guidelines emphasize that when using TLG for treatment response assessment, the same VOI approach must be used consistently for all PET/CT examinations in the same patient 1. This allows tracking of changes rather than comparison to population norms.
Measurement Variability Considerations
TLG variability increases exponentially with higher threshold percentages used for lesion delineation. At the commonly used 40% threshold, measurement error and repeatability range from 14.5%-20.4% 5. This inherent variability further argues against establishing fixed "normal" cutoffs.
Important Caveats
- TLG values are tumor-type specific: Cutoff values that predict outcomes in one cancer type (e.g., TLG >250 in sarcoma) cannot be applied to other malignancies
- Methodology matters: TLG values depend heavily on the delineation method used (VOI41 vs VOI50), making cross-study comparisons problematic
- No benign tissue baseline exists: Unlike SUVmax which can be measured in normal organs (liver, blood pool), TLG requires a defined lesion
The clinical utility of TLG lies in comparing values within the same patient over time or stratifying risk within specific tumor populations using validated cutoffs from clinical trials—not in comparing to a universal normal range.